Here’s why Oxford Nanopore Technologies stock is up 15% in the FTSE 250

This innovative FTSE 250 stock has had a solid start to the year, rising 15% in just two days. Is it time I considered adding it to my portfolio?

| More on:

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Oxford Nanopore Technologies (LSE: ONT) stock was the biggest riser in the FTSE 250 index yesterday (13 January). Shares of the gene-sequencing firm rose 10% then another 5% today to reach 149p.

However, the stock is still down more than 75% since listing in late 2021. Here, I’ll take a look at what has caused the recent jump and assess whether it’s a good fit for my portfolio.

Encouraging update

For those unfamiliar, Oxford Nanopore makes cutting-edge DNA/RNA sequencing devices that enable real-time analysis of genetic material. They’re used for scientific research across the healthcare and life sciences industries.

Yesterday, the firm released a full-year trading update. In this, we learnt that underlying revenue growth in the second half was approximately 34% at constant currency. This was an acceleration over the first half, enabling the company to achieve £183m in revenue, in line with market expectations.

That would represent year-on-year growth of 11% on a constant currency basis. That’s not bad considering the overall life sciences sector faced challenging conditions in 2024.

CEO Gordon Sanghera commented: “Looking beyond 2025, our highly differentiated platform and deep innovation pipeline coupled with strengthened commercial and operational capabilities combined with a strong balance sheet, position us well to deliver long-term, sustainable, above-market growth.”

Encouragingly, the gross margin is set to be slightly above the previously expected 57%. And management anticipates the gross margin reaching 62% by 2027, with revenue growing at a compound annual growth rate of more than 30% between 2024 and that date. It also reaffirmed a target of adjusted EBITDA breakeven in 2027.

No profits yet

Of course, an ambition to reach adjusted EBITDA breakeven in two years indicates that the firm is still deeply unprofitable. Indeed, it doesn’t expect to become cash flow positive until at least 2028.

Clearly, the losses add risk to the investment case. And they almost certainly explain why the share price has struggled since late 2021 when the era of near-0% interest rates came to an end.

We won’t get the full-year earnings until 4 March. Looking at the forecasts though, I’m seeing losses above £100m for both last year and this one.

On the plus side, the firm ended 2024 with £403m in cash, so remains well-capitalised. It should be capable of becoming cash flow positive with the resources at hand. If it can do so, while hitting its revenue growth targets, the share price could end up much higher than today’s 149p.

Should I invest?

Oxford Nanopore’s products are based on innovative technology and it appears to be taking market share during a challenging time. The more devices it sells, the more recurring revenue it gets from consumables and software services.

With a modest market cap of £1.4bn, the firm could become a takeover target. However, it can be dangerous to invest on the basis that a business might be acquired at a higher price.

Recently, I’ve made a hash of picking stocks in the healthcare sector. My holding in Moderna continues to take a battering (down another 16% yesterday), while medical device firm Creo Medical has unperformed too. Even Novo Nordisk is struggling lately.

With Oxford Nanopore stock trading at a premium 7.6 times sales, I’m going to give this one a miss for now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Creo Medical Group Plc, Moderna, and Novo Nordisk. The Motley Fool UK has recommended Moderna and Novo Nordisk. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

With an 8% yield and a P/E below 12, Taylor Wimpey looks in deep value territory

Harvey Jones wants to make a bit of noise about Taylor Wimpey shares. The FTSE 100 stock may be volatile…

Read more »

A young Asian woman holding up her index finger
Investing Articles

Up 8% today, is this one of the FTSE 100 best growth shares to buy?

Looking for the best FTSE 100 growth shares for a winning portfolio? This soaring blue chip is worth serious consideration,…

Read more »

Investing Articles

With yields over 7%, here are two FTSE 100 dividend shares to consider in 2025

As the FTSE 100 trades near all-time highs in 2025, some of its top dividend shares still offer highly attractive…

Read more »

Investing Articles

Here’s why Coca-Cola HBC stock jumped over 9% in the FTSE 100 today

This stock was flying to a record high in the FTSE 100 today, boosted by a strong set of earnings.…

Read more »

Investing Articles

1 FTSE 100 stock an investor consider for a Stocks and Shares ISA if Cash ISAs get canned

The talk in the papers is of the Cash ISA getting axed, but the Stocks and Shares ISA seems secure.…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

A 5.5% dividend forecast? £2k invested in Lloyds shares could earn an investor this much by 2027

Jon Smith talks through the dividend forecast for Lloyds stock in the coming years and weighs up whether it could…

Read more »

Investing Articles

How much in savings would investors need to target a £3,000 monthly passive income?

Our writer outlines a simple recipe to earn passive income from shares. The ingredients include diligent saving, ample time and…

Read more »

Investing Articles

The average Stocks and Shares ISA turned £10k into £25k in a decade. I aim to beat that

Harvey Jones is impressed by the long-term total return on the average Stocks and Shares ISA. Yet he still reckons…

Read more »